ǰÑÔ
Âѳ²°©(ovarian carcinoma)ÊÇÅ®ÐÔÉúֳϵͳ³£¼ûµÄ¶ñÐÔÖ×Áö£¬Æä·¢²¡ÂÊ¡¢²¡ËÀÂʾù¾Ó¸¾¿Æ¶ñÐÔÖ×ÁöǰÏß¡£ÏÖÔÚ½¨ÉèÂѳ²°©¶¯ÎïÄ£×ÓµÄÒªÁìÓÐ×Ô¾õÐÔµÄÂѳ²Ö×Áö¶¯ÎïÄ£×Ó¡¢ÌåÍâת»¯Âѳ²ÉÏÆ¤Ï¸°ûµÄÒÆÖ²Áö¡¢Ö°©ÎïÓÕ·¢Âѳ²Ö×ÁöÒÔ¼°»ùÒò¹¤³ÌÂѳ²Ö×Áö¶¯ÎïÄ£×Ó¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
½«»¯Ñ§Ö°©¼Áͨ¹ý¾Ö²¿°üÂñµÈÒªÁìÖ±½Ó×÷ÓÃÓÚ×éÖ¯ÖУ¬ÕâЩÖ°©Îï×÷ÓÃÓÚÂѳ²ÍâòÉÏÆ¤£¬ÒýÆðϸ°ûµÄת»¯£¬Í¬Ê±Ò²ÓпÉÄÜͨ¹ý¶ÔÂÑÅݺͣ¨»ò£©¶ÔÂÑĸϸ°ûµÄÆÆË𣬸ıä´ÙÐÔÏÙ¼¤ËصÄˮƽ¶ø±¬·¢Âѳ²Ö×Áö¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
Óñ½ÈܼÁÏûÈÚDMBAºó£¬½«ÃÞÏß½þÈëÒ©Òº£¬ÖÃÓÚ͸·ç³÷ÄÚ´ý±½»Ó·¢ºó£¬ÅÌËãÃÞÏߵĺ¬Ò©Á¿Îª0.5mg/cm¡£8ÖÜÁäF344´ÆÐÔ´óÊóÒÔÎì°Í±ÈÍ×ÄÆ¸¹Ç»×¢ÉäÂé×í£¬ÎÞ¾úÌõ¼þÏÂÓÚϸ¹ÕýÖС¢³Ü¹ÇÍŽáÉÏ1cm×ÝÐÐÇпª¸¹±ÚÔ¼1.5cm£¬³ä·Ö̻¶Âѳ²ºóÓÃ5ºÅ¿ÉÎüÊÕ·ìÏß½«1¸ùº¬Ò©ÃÞÏß·ìÈë´óÊóÂѳ²£¬¹Ø¸¹¡£Ã¿ÖÜÿֻ´óÊó¸¹Ç»×¢ÉäÇì´óÃ¹ËØ0.1ml¡£
ÆäËûÒªÁ죺ÔÚ»áÒõ²¿Ê¹Óû¬Ê¯·Û£¬¿É˳×ÅÉúÖ³µÀµÖ´ïÂѳ²Íâò¶ø±¬·¢Ö°©×÷Ó㻽«»¬Ê¯·ÛÖ±½Ó×÷ÓÃÓÚÂѳ²Íâò£¬¿ÉÒÔÒýÆð¾Ö²¿ÈéÍ·×´¸Ä±äºÍÂѳ²ÄÒÖס£»¯Ñ§ÎïDMBA×÷ÓÃÓÚ´óÊóµÄÂѳ²Íâò£¬¿ÉÒÔÒý·¢ÉÏÆ¤ÐÔÖ×Áö£¬Í¬Ê±¼ì²â»¹·¢Ã÷ÓÐp53ºÍK-ras»ùÒòµÄÍ»±ä¡£½«ºãºÓºïºÍ⨺ï̻¶ÔÚһЩɱ³æ¼Á£¬ÈçÁùÂȱ½ÎÛȾµÄÇéÐΣ¬¿ÉÒÔÓÕ·¢Âѳ²ÉúÓý¹¦Ð§µÄË¥½ß¡¢Âѳ²¾Þϸ¡¢ÐÎ×´µÄÏÔןıäÒÔ¼°OSEÅÅÁÐÌõÀíµÄ¸Ä±ä¡£
¡¾Ä£×ÓÌØµã¡¿£º
ÊõºóµÚ6ÖÜ×îÏÈÓÐÖ×ÁöÐγɣ¬²¢Óи¹Ä¤µÈ²¿Î»×ªÒÆÔîÐγɡ£ÔìÄ£¶¯Îï·ºÆðÏûÊÝ¡¢ÍÜ×´¸¹¡¢¸¹Ç»ÑªÐÔ¸¹Ë®¡¢ÑªÐéò£¨ÑÛÇò²Ò°×¡¢¶úÀª²Ò°×£© Ë¥½ßµÈÂѳ²°©µä·¶µÄÁÙ´²ÌåÏÖ¡£Óû¯Ñ§ÎïÖʴ̼¤Äö³ÝÀදÎïµÄÂѳ²±¬·¢¶¾ÐÔºÍÖ°©ÐÔ£¬µ¼ÖÂÂÑÅݵĿÝή£¬±¬·¢Á£²ãϸ°ûÁöºÍÁ¼ÐԵĻìÏýÁö¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
»¯Ñ§Ò©Îï¾Ö²¿×÷ÓÃÊÇÒ»ÖÖ½ÏΪֱ½ÓµÄÓÕµ¼Ö×ÁöÒªÁ죬¿ÉÊÇÐèÒª¶ÔʵÑéÓÃÊó¾ÙÐÐÊÖÊõµÈ²Ù×÷£¬ÈÝÒ×Ôì³ÉѬȾ£¬ÉõÖÁéæÃü¡£Í¬Ê±£¬ÈôÊǼÁÁ¿Ì«Ð¡Ê±£¬ÆäDZÔÚÆÚ¿ÉÁè¼Ý¶¯ÎïÊÙÃü£¬µ¼ÖÂÖ°©ÂʽµµÍ¡£±¾¶¯ÎïÄ£×ÓÔÚÖ×ÁöÉú³¤·½·¨¡¢¼²²¡Ï£ÍûÀú³Ì¡¢²¢·¢Ö¢µÈ·½ÃæÓëÈËÂѳ²°©ÀàËÆ£¬ÊǽÏΪÀíÏëµÄÂѳ²°©¶¯ÎïÄ£×Ó¡£
²Î¿¼ÎÄÏ×£º
1.Òü°®À¼£¬ÖÓ÷£¬Ëï¹ðÇÛ£¬µÈ£®ÂÌɫӫ¹âÂѰױê¼ÇµÄÈËÂѳ²°©ÂãÊóÔÎ»ÒÆÖ²Ä£×ӵĽ¨É裮ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2008,28 (3):484-486
2.ãÆÖÒöΣ¬º«·ï¾ê£¬µÔСÁú£¬µÈ£®Âѳ²°©ÂãÊóÒÆÖ²ÁöÄ£×Ó±ÈÕպͿÉÊÓ»¯Ñо¿Ï£Íû£®ÌìÏÂÖÐÎ÷ҽ͎áÔÓÖ¾£¬2012, 7 (7):636-638
3.ÇñÀö骣¬º«·ç¾ê£¬·¶ÏÔ×Å£¬µÈ£®Á½ÖÖÓÕ·¢Fischer344´óÊóÂѳ²°©¶¯ÎïÄ£×Ó½¨ÉèÒªÁìµÄ½ÏÁ¿. ÌìÏÂÖÐÎ÷ҽ͎áÔÓÖ¾£¬2010,5(6):488-490
4.Ò¦µÂÉú£®ÖØ×鷴ת¼²¡¶¾½éµ¼µÄk-Ras/c-MycСÊóÂѳ²°©¶¯ÎïÄ£×ӵĽ¨ÉèºÍÒÖ°©»ùÒòOPCMLµÄ¿Ë¡¼°ÆäÔÚÂѳ²°©ÖеĹ¦Ð§Ñо¿£®¹ãÎ÷Ò½¿Æ´óѧ²©Ê¿Ñ§Î»ÂÛÎÄ£¬2005
5.Àè¾²£¬ÍõÑ©·É£¬ÖÓ÷£®ÕûÌå¿ÉÊÓ»¯Âѳ²°©Ôλ¼°×ªÒƶ¯ÎïÄ£×ӵĽ¨É裮¹ã¶«Ò½Ñ§£¬2012, 33 (7):887-889
6.öÄȫУ¬ÃÓÈôÈ». ת»ùÒò¶¯ÎïÔÚÂѳ²Ö×ÁöÑо¿ÖеÄÓ¦Óã®ÍâÑóҽѧ¸¾²ú¿ÆÑ§·Ö²á£¬2003,30 (6):391-393
7.Connolly DC, Bao R, Nikitin AY, el al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MlSilR promoter develop epithelial ovarian cancer, Cancer res 2003, 63 (6): 1389-1397
8.Dutertre M, Couédard L, Xavier F, el al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice. Endocri.nology, 2001, 142 (9):4040-4046
9.Carson K, Macdonald E, Dube M, et al. Generali on of tumors in transgece mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. J Soc Cynecol lnvestig,2003,10(4):244-250
10.Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherap. Methods Mol Med,2005, 111 :297-322
11.Kananen K, Markkula M, Rainio E, et al. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol, 1995,9 (5):616-627
12.Selvakumaran M, Bao R, Crijns AP, el al. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res,2001, 61 (4):1291-1295